



# Health Research Authority

## NRES Committee London - South East

Bristol Research Ethics Committee Centre  
Level 3, Block B  
Whitefriars,  
Lewins Mead,  
Bristol  
BS1 2NT

Telephone: (0117) 3421382  
Facsimile: (0117) 3420445

29 January 2014

Professor Philip M. W. Bath  
Professor of Stroke Medicine  
University of Nottingham  
Division of Stroke Medicine - Research Dept  
Clinical Sciences Building  
City Hospital Campus  
Hucknall Road  
Nottingham NG5 1PB

Dear Professor Bath

**Study Title:** Safety and tolerability of clopidogrel when added to aspirin and dipyridamole in high risk patients with recent ischaemic stroke: a randomised controlled trial

**REC reference:** 08/H1102/112

**Protocol number:** 31350

**EudraCT number:** 2007-006749-42

**Amendment number:** AM27: SA05/13 dated 17 December 2013

**Amendment date:** 17 December 2013

Thank you for submitting the above amendment, which was received on 18 December 2013.

Research Site	Principal Investigator / Local Collaborator
Western Sussex Hospitals Foundation Trust, St. Richard's Hospital, Spitalfield Lane, Chichester PO19 6SE	Dr Simone Ivatts
South Eastern Health and Social Care Trust, The Ulster Hospital, Upper Newtownards Road, Dundonald, Belfast BT16 1 RH	Dr Michael Power
Homerton University Hospital NHS Foundation Trust, Homerton Hospital, Homerton Row, London E9 6SR	Dr Anthea Lehmann
City Hospitals Sunderland NHS Foundation Trust, Sunderland Royal Hospital, Education	Dr Janice O'Connell

Centre, Kayll Road, Sunderland, Tyne & Wear SR4 7TP	
The Dudley Group NHS Foundation Trust, Russells Hall Hospital, Dudley, West Midlands DY1 2QH	Dr Ashim Banerjee

The amendment relates solely to the addition of new site(s) and/or investigator(s) within the National Health Service (NHS) or Health and Social Care (HSC) in Northern Ireland. The site-specific assessment for the site(s) will therefore form part of the research governance review. The Site-Specific Information (SSI) Form for the site should be included with the application for R&D approval.

On behalf of the Committee, I am pleased to confirm the extension of the favourable opinion to the new site(s) and/or investigator(s), subject to management permission being given by the relevant NHS/HSC R&D office(s) prior to the study starting at the site.

### **Statement of compliance**

This Committee is recognised by the United Kingdom Ethics Committee Authority under the Medicines for Human Use (Clinical Trials) Regulations 2004, and is authorised to carry out the ethical review of clinical trials of investigational medicinal products.


The Committee is fully compliant with the Regulations as they relate to ethics committees and the conditions and principles of good clinical practice.

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

**08/H1102/112**

**Please quote this number on all correspondence**

Yours sincerely



**Mr Wai Yeung**  
**Research Ethics Committee (REC) Assistant**

Email: [nrescommittee.london-southeast@nhs.net](mailto:nrescommittee.london-southeast@nhs.net)

Copy to: *Mr Paul Cartledge*